Cerebrolysin is a widely discussed neurotrophic peptide mixture. It is derived from porcine brain tissue and has been used clinically in parts of Europe and Asia for decades. The preparation is investigated for its potential to support neurorecovery after acute ischaemic stroke, traumatic brain injury, and neurodegenerative conditions such as Alzheimer's disease.
The search for effective neuroprotective agents has seen many failed drug candidates. Stroke and traumatic brain injury involve complex cascades of cellular damage, and single molecule drugs have frequently failed to translate from animal models to human success. Cerebrolysin is unique in this research space because it is a broad biological mixture rather than a single targeted synthetic compound.
What is Cerebrolysin actually made of?
Its biological origin creates a fundamental difference between Cerebrolysin and synthetic peptides. Synthetic peptides are manufactured via solid phase peptide synthesis to an exact sequence. A biological hydrolysate has inherent complexity, although manufacturers use standardisation processes to ensure consistent biological activity across different batches.
Because it is a complex mixture, researchers cannot isolate a single receptor target. Instead, preclinical studies suggest the preparation stimulates molecular signalling pathways. Mechanistic 1 The proposed mechanism is that the small peptide fractions cross the blood brain barrier and interact with multiple signalling cascades involved in neuroprotection and repair.
Because of its complex biological nature and the volume required to achieve therapeutic concentrations, it is not formulated for the small volume subcutaneous injections typically used for synthetic peptides. This requirement for clinical administration adds a layer of complexity to its use and limits its application outside of hospital or supervised clinical environments.
Acute ischaemic stroke: the largest trial record
The most extensive human data for Cerebrolysin comes from trials in acute ischaemic stroke. The clinical goal of these studies is to determine whether early administration can protect brain tissue or improve functional recovery. Time is a critical factor in stroke treatment, and neuroprotective agents aim to salvage the penumbra, which is the area of brain tissue that is damaged but not yet dead.
The results across the trial record are mixed. The 2020 Cochrane review, updated in 2023, is the most rigorous independent assessment of the stroke data. It pooled data from multiple randomised controlled trials involving over 1,600 participants. The review authors specifically looked for hard clinical endpoints, primarily all cause mortality and the prevention of long term dependence. Dependence is typically measured by the modified Rankin Scale, a standard neurological tool that assesses the degree of disability in daily activities. The review concluded that Cerebrolysin probably results in little to no difference in all cause death, and noted that none of the included trials reported on long term dependence. Human 2
The Cochrane review also reported moderate quality evidence of an increase in non fatal serious adverse events among patients receiving the preparation compared to those receiving placebo. Human 2
Individual trials have reported different findings. The CARS trial was a randomised, placebo controlled multicentre study. It focused on early rehabilitation, administering the preparation alongside a standardised physical therapy programme. The trial reported a positive result on its primary endpoint, the Action Research Arm Test at day 90. Human 3
The CASTA study provides another perspective. It randomised 1,070 patients, making it one of the largest single trials for this preparation. The primary confirmatory endpoint was neutral, meaning the trial failed to prove overall efficacy across the broad stroke population. A post hoc subgroup analysis suggested a potential mortality reduction in patients with severe stroke, defined by a National Institutes of Health Stroke Scale score above 12. Because this was a post hoc analysis, it is considered a hypothesis generating signal rather than a definitive clinical conclusion. Human 4
A separate 2017 pooled analysis by Bornstein and colleagues, which included nine trials, reported superiority of Cerebrolysin compared to placebo for early global neurological improvement. Human 5 This divergence in interpretation illustrates why the clinical verdict remains contested. Independent Cochrane reviewers see no hard clinical benefit on mortality or dependence, while other analyses report functional gains.
Traumatic brain injury: functional recovery signals
Traumatic brain injury presents a different pathophysiological challenge. It involves primary mechanical damage followed by secondary injury cascades including oedema, inflammation, and oxidative stress. These secondary cascades are the primary target for neuroprotective therapies, as mitigating them can prevent further tissue loss in the days following the initial trauma.
The CAPTAIN trial series investigated the preparation as an add on therapy to standard care for moderate to severe traumatic brain injury. A prospective pooled analysis of the CAPTAIN trials, which included 185 patients, evaluated a multidimensional ensemble of functional and neuropsychological outcome scales. The analysis reported a small to medium sized effect in favour of Cerebrolysin at 30 and 90 days post injury. Human 6
Other systematic reviews in this indication have reported improvements in the Glasgow Outcome Scale and the modified Rankin Scale. Human 7
While these findings suggest a potential role in supporting functional recovery after head trauma, the trials are generally smaller and less definitive than those conducted for acute stroke. The data supports early functional improvements, but long term structural brain repair remains difficult to prove in human subjects.
Dementia and cognitive impairment
Neurodegenerative diseases like Alzheimer's disease and vascular dementia involve progressive neuronal loss. Cerebrolysin has been studied in these populations to see if its neurotrophic properties can slow cognitive decline or improve daily functioning.
A 2015 systematic review of six randomised controlled trials in mild to moderate Alzheimer's disease evaluated the preparation's effect on cognitive function. The analysis found that Cerebrolysin was significantly more effective than placebo at four weeks. The same analysis found that the cognitive benefit was not maintained at six months. Human 8
In vascular dementia, a 2019 Cochrane review updated the evidence base. The review reported inconsistent results across trials. While some individual studies showed positive effects on cognitive and global function, the overall strength of the evidence was limited. The reviewers concluded that there was insufficient high quality evidence to support routine clinical use for vascular dementia. Human 9
The clinical data indicates that while the peptide mixture may offer short term cognitive support or symptom relief, long term disease modification in progressive neurodegenerative conditions remains unproven.
Safety and theoretical risks
Because Cerebrolysin is derived from porcine brain tissue, its safety profile is frequently scrutinised. In clinical trials, its safety profile is generally reported to be comparable to placebo. Human 5
The 2023 Cochrane review for acute ischaemic stroke noted an increase in non fatal serious adverse events. Human 2
This biological origin is a primary reason why regulatory agencies in some countries require exceptional safety data before considering approval.
The WADA position
For athletes, Cerebrolysin is not explicitly named on the World Anti-Doping Agency (WADA) Prohibited List. Because it is a pharmacological preparation containing peptide fractions, its status is unsettled. It may fall under the S0 (Unapproved Substances) or S2 (Peptide Hormones, Growth Factors) catch all categories depending on the jurisdiction and the specific anti doping organisation's interpretation. 10
The BioRx conclusion
Cerebrolysin is a complex biological mixture with a substantial clinical trial record, but the data does not provide a single clear answer. While large pooled analyses in acute stroke show little to no difference in mortality and lack data on long term dependence, smaller trials and specific subgroups often report early functional and cognitive improvements in stroke, traumatic brain injury, and dementia.
Because it is a porcine derived hydrolysate rather than a single synthetic peptide, its mechanism remains broad and difficult to isolate.
For the broader biology, see What Are Peptides?.
UK regulatory context
Cerebrolysin does not hold a UK marketing authorisation. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates such products as unlicensed medicines. Under the Human Medicines Regulations 2012, unlicensed medicines may only be supplied to meet the special clinical needs of an individual patient. 11
Frequently asked questions
What is Cerebrolysin?
It is a biological mixture of low molecular weight peptides and amino acids derived from porcine brain tissue.
What do the human trials in stroke show?
The largest pooled analyses, including a 2023 Cochrane review, found little to no difference in all cause death and noted a lack of data on long term dependence, though some individual trials report early functional improvements.
How is it different from synthetic peptides?
Synthetic peptides are manufactured to an exact amino acid sequence. Cerebrolysin is a biological hydrolysate containing multiple peptide fractions.
Is Cerebrolysin licensed in the UK?
No. It does not hold a UK marketing authorisation. The MHRA regulates it as an unlicensed medicine, which under the Human Medicines Regulations 2012 may only be supplied to meet the special clinical needs of an individual patient.
Is Cerebrolysin banned by WADA?
It is not explicitly named on the WADA Prohibited List, but as a pharmacological preparation containing peptides, it may fall under catch all categories such as S0 or S2 depending on the anti doping organisation's interpretation.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- PubMed, PMID 33515100
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews.PubMed · DOI · View study in BioRx
- Muresanu DF, Heiss WD, Hoemberg V et al. (2016). Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- PubMed, PMID 29248999
- PubMed, PMID 33620612
- PubMed, PMID 30643411
- PubMed, PMID 25832905
- Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L (2019). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews.PubMed · DOI · View study in BioRx
- WADA, Prohibited List 2026
- MHRA, Supply unlicensed medicinal products (specials)
